First data from the KITE and KESTREL trials showed encouraging efficacy and safety outcomes of brolucizumab in the treatment of diabetic macular edema.
“Both studies demonstrated that brolucizumab 6 mg was noninferior to aflibercept in mean change of [best corrected visual acuity] at week 52 with fewer injections. Central subfield thickness improved significantly, and there was a higher proportion of patients with fluid resolution,” David M. Brown, MD, said at the virtual Association for Research in Vision and Ophthalmology meeting.
The safety profile was, overall, “well balanced,”